Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club

Regulatory Affairs
Return to: PBR Home | Regulatory Affairs

Regulatory Affairs

Lilly's Trulicity type 2 diabetes drug gets FDA approval By PBR Staff Writer
Eli Lilly and Company has received approval from the US Food and Drug Administration for Trulicity (dulaglutide) as a treatment option for adults with type 2 diabetes.
Regulatory Affairs > News
Soligenix secured FDA clearance of Phase III trial of lymphoma drug SGX301 By PBR Staff Writer
US-based biopharmaceutical firm Soligenix has entered into an agreement with the US Food and Drug Administration (FDA) on the design of a major Phase III clinical trial assessing its product SGX301 (synthetic hypericin) to treat cutaneous T-cell lymphoma (CTCL).
Regulatory Affairs > News GSK resolves risk management violation issue at Montana facility in US By PBR Staff Writer
British drug-maker GlaxoSmithKline (GSK) has resolved the issue of Clean Air Act violation, associated with its failure to submit a risk management plan at its facility in Hamilton, Montana, US.
Regulatory Affairs > News
See more Regulatory Affairs news

Latest Regulatory Affairs News and Insight

View all Regulatory Affairs news or find news targeted to your interests
Soligenix secured FDA clearance of Phase III trial of lymphoma drug SGX301
By PBR Staff Writer
US-based biopharmaceutical firm Soligenix has entered into an agreement with the US Food and Drug Administration (FDA) on the design of a major Phase III clinical trial assessing its product SGX301 (synthetic hypericin) to treat cutaneous T-cell lymphoma (CTCL).
Regulatory Affairs > News
GSK resolves risk management violation issue at Montana facility in US
By PBR Staff Writer
British drug-maker GlaxoSmithKline (GSK) has resolved the issue of Clean Air Act violation, associated with its failure to submit a risk management plan at its facility in Hamilton, Montana, US.
Regulatory Affairs > News
FDA committee recommends approval of Natpara to treat hypoparathyroidism
NPS Pharmaceuticals, a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, has announced that the U.S. Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 8 to 5 that the available data support the approval of Natpara (rhPTH [1-84]) for the long-term treatment of Hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of parathyroid hormone, or PTH.
Regulatory Affairs > News
US FDA approves Baxter and Halozyme's Hyqvia to treat primary immunodeficiency
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted approval for Baxter and Halozyme Therapeutics' Hyqvia as a subcutaneous treatment for adult patients with primary immunodeficiency (PI).
Regulatory Affairs > News
FDA approves Takeda and Orexigen's Contrave for chronic weight management
By PBR Staff Writer
The US Food and Drug Administration (FDA) has approved Takeda Pharmaceuticals USA and Orexigen Therapeutics’ Contrave (naltrexone HCI and bupropion HCI) extended-release tablets for chronic weight management.
Regulatory Affairs > News
FDA grants orphan drug status for Viamet's VT-1129 to treat cryptococcal meningitis
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted orphan drug designation for Viamet Pharmaceuticals' VT-1129, a potent and selective, oral, antifungal agent, to treat cryptococcal meningitis, a life-threatening invasive fungal infection of the lining of the brain and spinal cord.
Regulatory Affairs > News
Lilly and Boehringer's insulin glargine product gets European marketing approval
By PBR Staff Writer
Eli Lilly and Company and Boehringer Ingelheim have received marketing authorization from the European Commission (EC) for their insulin glargine product to treat diabetes in adults, adolescents and children aged two years and above.
Regulatory Affairs > News
Roche's RoACTEMRA gets European approval to treat early rheumatoid arthritis
By PBR Staff Writer
The European Commission has approved Roche's RoACTEMRA (tocilizumab) for use in patients with severe, active and progressive rheumatoid arthritis (RA) who previously have not been treated with methotrexate (MTX).
Regulatory Affairs > News
FDA approves ferric citrate for CKD dialysis patients with hyperphosphatemia
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted approval for Keryx Biopharmaceuticals for ferric citrate (formerly Zerenex) to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Regulatory Affairs > News
FDA approves Merck's anti-PD-1 therapy Keytruda
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted approval for Merck's Keytruda (pembrolizumab) to treat patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Regulatory Affairs > News
View all Regulatory Affairs news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250